Customised DNA-based nanocarriers to boost heart healing - DNABEATS

Project summary

Myocardial infarction and its evolution towards heart failure is a leading cause of death in Europe. No curative treatment aside heart transplantation has been accomplished so far. DNABEATS aims to bring advanced materials to regenerate injured myocardium. Cutting-edge DNA nanotechnology is exploited for the fabrication of fully customised biocompatible DNA-based nanocarriers (DNCs) to achieve the cardio-targeted and efficient delivery of a regenerative microRNA. The therapeutic efficacy of DNCs will be assessed in human-derived cardiac cells, a ground-breaking aspect, that together with an exhaustive in vitro and in vivo biocompatibility investigation, will facilitate their future clinical application and industrial transfer. DNABEATS entails thus benefits for multiple stakeholders from industry to patients and clinicians. Sustainability is also present in the project and different dissemination and exploitation actions are planned to maximise the socio-economic impacts.

Project Details

Call

Call 2022


Call Topic

New strategies for advanced material-based technologies for health applications


Project start

01.09.2023


Project end

31.08.2026


Total project costs

866.862 €


Total project funding

707.514 €


TRL

2 - 4


Coordinator

Dr. Silvia Hernández Ainsa

UNIVERSIDAD DE ZARAGOZA, CALLE PEDRO CERBUNA 12, 50009 ZARAGOZA, Spain


Partners and Funders Details

Consortium Partner   Country Funder
UNIVERSIDAD DE ZARAGOZA
https://www.unizar.es
University Spain ES-AEI
University of Tartu
https://ut.ee/en
University Estonia EE-ETAG
FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON
https://www.iisaragon.es/
Research org. Spain ES-AEI
Vilnius University
https://vu.lt/
University Lithuania LT-LMT
Jagiellonian University
https://en.uj.edu.pl/
University Poland PL-NCN

Keywords

gene therapy, self-assembly, cardiac disease, regenerative medicine, DNA nanotechnology, Targeted delivery